Lingling Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lingling Sun has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Beibei Ma
Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
1 shared publication - Bing Luo
Department of Pathogenic Biology, School of Basic Medicine Qingdao University Qingdao China
1 shared publication - Bing Wang
Biomedical Centre, Qingdao University, 308 Ningxia Road, Qingdao, 266071, China
1 shared publication Danrui Zhao
Department of Medical Microbiology, Qingdao University Medical College, Qingdao, China
1 shared publication- Feng Hou
The Affiliated Hospital of Qingdao University
1 shared publication - Haiyan Gu
Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China
1 shared publication
Latest Publications
- 27 April 2026
- Published by Taylor & Francis in Cell Cycle
- Vol. 25 (1) , 1-18
CTDSPL2 facilitates resistance to paclitaxel in breast cancer cells by suppressing SCYL1 phosphorylation
Breast cancer (BC) exhibits significant heterogeneity and complexity and is leading causes of mortality in women globally. Paclitaxel (PTX) is commonly utilized as the primary medication for BC. However, the resistance of BC to PTX poses a significant challenge in clinical treatment. This study aimed at to explore whether carboxy-terminal domain small phosphatase like 2 (CTDSPL2) affected PTX resistance in BC cells. PTX resistant BC cell lines, including MCF-7/PTX and MDA-MB-231/PTX, were developed by continuously increasing PTX concentration, and we found that CTDSPL2 was upregulated in BC cells with PTX resistance. Loss-of-function studies showed that CTDSPL2 knockdown caused a decrease in cytotoxicity and proliferative ability in PTX-resistant BC cells, as well as enhanced cell apoptotic rate and DNA damage. The results from nanoparticle tracking analysis (NTA) indicated that CTDSPL2 knockdown also suppressed the secretion of extracellular vesicles. In vivo tumorigenesis assays showed that CTDSPL2 downregulation inhibited tumorigenicity of nude mice injecting with PTX-resistant BC cells. Co-immunoprecipitation (Co-IP) assay demonstrated the binding between CTDSPL2 and SCY1-like pseudokinase 1 (SCYL1). The increased level of SCYL1 phosphorylation evoked by CTDSPL2 knockdown in PTX-resistant cancer cells was blocked after mutating the serine 754 site of SCYL1 to alanine. In conclusion, the present study identifies CTDSPL2 as a new factor in BC that plays an essential role in PTX-resistant BC cells through the regulation of SCYL1 phosphorylation.
- 27 April 2026
- Published by Taylor & Francis in Cell Cycle
- Vol. 25 (1) , 1-18
CTDSPL2 facilitates resistance to paclitaxel in breast cancer cells by suppressing SCYL1 phosphorylation
Breast cancer (BC) exhibits significant heterogeneity and complexity and is leading causes of mortality in women globally. Paclitaxel (PTX) is commonly utilized as the primary medication for BC. However, the resistance of BC to PTX poses a significant challenge in clinical treatment. This study aimed at to explore whether carboxy-terminal domain small phosphatase like 2 (CTDSPL2) affected PTX resistance in BC cells. PTX resistant BC cell lines, including MCF-7/PTX and MDA-MB-231/PTX, were developed by continuously increasing PTX concentration, and we found that CTDSPL2 was upregulated in BC cells with PTX resistance. Loss-of-function studies showed that CTDSPL2 knockdown caused a decrease in cytotoxicity and proliferative ability in PTX-resistant BC cells, as well as enhanced cell apoptotic rate and DNA damage. The results from nanoparticle tracking analysis (NTA) indicated that CTDSPL2 knockdown also suppressed the secretion of extracellular vesicles. In vivo tumorigenesis assays showed that CTDSPL2 downregulation inhibited tumorigenicity of nude mice injecting with PTX-resistant BC cells. Co-immunoprecipitation (Co-IP) assay demonstrated the binding between CTDSPL2 and SCY1-like pseudokinase 1 (SCYL1). The increased level of SCYL1 phosphorylation evoked by CTDSPL2 knockdown in PTX-resistant cancer cells was blocked after mutating the serine 754 site of SCYL1 to alanine. In conclusion, the present study identifies CTDSPL2 as a new factor in BC that plays an essential role in PTX-resistant BC cells through the regulation of SCYL1 phosphorylation.
- Open Access
- 24 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (17) , e48426
Influence of metabolic syndrome on disease characteristics and activity in inflammatory bowel disease: A retrospective cohort study
The incidence of inflammatory bowel disease (IBD) and metabolic syndrome (MetS) has risen in recent years, but the relationship between the 2 remains understudied. This retrospective cohort study aimed to explore the impact of MetS on disease activity in IBD. Retrospective analysis of 676 consecutive IBD patients treated from January 2023 to April 2024. Study participants were stratified into a control cohort of 531 patients with uncomplicated IBD, and an exposure cohort of 145 patients with IBD and concurrent MetS. Data were collected and analyzed for all 676 patients at baseline and after 1-year follow-up. From an initial pool of 1730 potentially eligible patients, 156 (9%) were identified with MetS (IBD-MetS cohort: 86% ulcerative colitis and 14% Crohn’s disease). Baseline clinical disease activity was significantly higher than in the IBD-only controls, with concomitant elevations in biomarkers including monocytosis, eosinophilia, elevated C-reactive protein and elevated erythrocyte sedimentation rate. At 12-months’ follow-up, the IBD-MetS group showed significantly lower rates of clinical remission (54.48% vs 82.49%) and mucosal healing (24.83% vs 41.05%) compared to the controls. Inflammatory biomarkers remained elevated, consistent with baseline findings. After propensity score-matched analysis, a comparative analysis of 145 matched controls and 145 exposed groups showed that, compared to IBD-only patients, IBD-MetS patients still had significantly lower rates of clinical remission (54.48% vs 77.93%, odds ratio: 0.339, 95% confidence interval: 0.203–0.565, P < .001) and mucosal healing (24.83% vs 41.38%, odds ratio: 0.468, 95% confidence interval: 0.283–0.772, P = .003). Our findings indicate that MetS is correlated with increased disease activity in IBD. These findings emphasize the need for clinicians to identify and intervene in metabolic syndrome components in IBD patients, ultimately improving quality of life and providing new insights for future IBD-MetS research.
- 24 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (17) , e48426
Open AccessInfluence of metabolic syndrome on disease characteristics and activity in inflammatory bowel disease: A retrospective cohort study
The incidence of inflammatory bowel disease (IBD) and metabolic syndrome (MetS) has risen in recent years, but the relationship between the 2 remains understudied. This retrospective cohort study aimed to explore the impact of MetS on disease activity in IBD. Retrospective analysis of 676 consecutive IBD patients treated from January 2023 to April 2024. Study participants were stratified into a control cohort of 531 patients with uncomplicated IBD, and an exposure cohort of 145 patients with IBD and concurrent MetS. Data were collected and analyzed for all 676 patients at baseline and after 1-year follow-up. From an initial pool of 1730 potentially eligible patients, 156 (9%) were identified with MetS (IBD-MetS cohort: 86% ulcerative colitis and 14% Crohn’s disease). Baseline clinical disease activity was significantly higher than in the IBD-only controls, with concomitant elevations in biomarkers including monocytosis, eosinophilia, elevated C-reactive protein and elevated erythrocyte sedimentation rate. At 12-months’ follow-up, the IBD-MetS group showed significantly lower rates of clinical remission (54.48% vs 82.49%) and mucosal healing (24.83% vs 41.05%) compared to the controls. Inflammatory biomarkers remained elevated, consistent with baseline findings. After propensity score-matched analysis, a comparative analysis of 145 matched controls and 145 exposed groups showed that, compared to IBD-only patients, IBD-MetS patients still had significantly lower rates of clinical remission (54.48% vs 77.93%, odds ratio: 0.339, 95% confidence interval: 0.203–0.565, P < .001) and mucosal healing (24.83% vs 41.38%, odds ratio: 0.468, 95% confidence interval: 0.283–0.772, P = .003). Our findings indicate that MetS is correlated with increased disease activity in IBD. These findings emphasize the need for clinicians to identify and intervene in metabolic syndrome components in IBD patients, ultimately improving quality of life and providing new insights for future IBD-MetS research.
- 1 September 2022
- Published by Taylor & Francis in Fetal and Pediatric Pathology
- Vol. 42 (2) , 320-326
Distal Femoral Non-Epiphyseal Cortical Chondroblastoma Confirmed with H3F3B p. Lys36Met Mutation
Background: Chondroblastoma is a primary bone tumor typically arising from the intramedullary space of the epiphysis or epimetaphysis. A non-epiphyseal chondroblastoma is uncommon. Case report: An 11-year-old girl presented with an eccentric cortical osteolytic lesion in the distal femur metaphysis. The typical morphology, diffuse H3.3 K36M immunohistochemical expression and H3F3B point mutation (c. 110A > T) unequivocally supported the diagnosis of chondroblastoma. Discussion: We described a non-epiphyseal cortical-based chondroblastoma involving the distal femur harboring the typical H3F3B mutation. Non-epiphyseal chondroblastoma may harbor the H3F3B mutation.
- 1 September 2022
- Published by Taylor & Francis in Fetal and Pediatric Pathology
- Vol. 42 (2) , 320-326
Distal Femoral Non-Epiphyseal Cortical Chondroblastoma Confirmed with H3F3B p. Lys36Met Mutation
Background: Chondroblastoma is a primary bone tumor typically arising from the intramedullary space of the epiphysis or epimetaphysis. A non-epiphyseal chondroblastoma is uncommon. Case report: An 11-year-old girl presented with an eccentric cortical osteolytic lesion in the distal femur metaphysis. The typical morphology, diffuse H3.3 K36M immunohistochemical expression and H3F3B point mutation (c. 110A > T) unequivocally supported the diagnosis of chondroblastoma. Discussion: We described a non-epiphyseal cortical-based chondroblastoma involving the distal femur harboring the typical H3F3B mutation. Non-epiphyseal chondroblastoma may harbor the H3F3B mutation.
- 10 January 2018
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 9 (2) , 1214-1223
The effect of fucoidan on intestinal flora and intestinal barrier function in rats with breast cancer
Recent research studies have shown that the intestinal flora are related to the occurrence and progress of breast cancer. This study investigates the effect of fucoidan on intestinal flora and intestinal barrier function in rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancers. Sixty female Sprague-Dawley rats were randomly assigned to the control group, the model group, and the F1 and F2 groups, which were fed fucoidan at concentrations of 200 and 400 mg per kg bw (body weight), respectively. Intestinal histopathological analysis was performed and 16S rDNA high-throughput sequencing was used to provide an overview of the intestinal flora composition. The contents of D-lactic acid (D-LA), diamine oxidase (DAO) and endotoxin in plasma were detected by ELISA. Expression levels of the tight junction (TJ) proteins, phosphorylated p38 MAPK and ERK1/2 were measured using western blotting. Our results suggested that the intestinal wall of the model group was damaged. However, after fucoidan intervention, the villi were gradually restored. ELISA showed that the levels of plasma endotoxin, D-LA and DAO decreased in the F1 and F2 groups compared to those in the model group. Fucoidan treatment also increased the expressions of ZO-1, occludin, claudin-1 and claudin-8. Furthermore, the expression levels of phosphorylated p38 MAPK and ERK1/2 were upregulated in fucoidan treatment groups. The results of 16S rDNA high-throughput sequencing indicated that fucoidan increased the diversity of the intestinal microbiota and induced changes in microbial composition, with the increased Bacteroidetes/Firmicutes phylum ratio. In conclusion, the supplement of fucoidan could improve the fecal microbiota composition and repair the intestinal barrier function. The study suggested the use of fucoidan as an intestinal flora modulator for potential prevention of breast cancer.
- 10 January 2018
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 9 (2) , 1214-1223
The effect of fucoidan on intestinal flora and intestinal barrier function in rats with breast cancer
Recent research studies have shown that the intestinal flora are related to the occurrence and progress of breast cancer. This study investigates the effect of fucoidan on intestinal flora and intestinal barrier function in rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancers. Sixty female Sprague-Dawley rats were randomly assigned to the control group, the model group, and the F1 and F2 groups, which were fed fucoidan at concentrations of 200 and 400 mg per kg bw (body weight), respectively. Intestinal histopathological analysis was performed and 16S rDNA high-throughput sequencing was used to provide an overview of the intestinal flora composition. The contents of D-lactic acid (D-LA), diamine oxidase (DAO) and endotoxin in plasma were detected by ELISA. Expression levels of the tight junction (TJ) proteins, phosphorylated p38 MAPK and ERK1/2 were measured using western blotting. Our results suggested that the intestinal wall of the model group was damaged. However, after fucoidan intervention, the villi were gradually restored. ELISA showed that the levels of plasma endotoxin, D-LA and DAO decreased in the F1 and F2 groups compared to those in the model group. Fucoidan treatment also increased the expressions of ZO-1, occludin, claudin-1 and claudin-8. Furthermore, the expression levels of phosphorylated p38 MAPK and ERK1/2 were upregulated in fucoidan treatment groups. The results of 16S rDNA high-throughput sequencing indicated that fucoidan increased the diversity of the intestinal microbiota and induced changes in microbial composition, with the increased Bacteroidetes/Firmicutes phylum ratio. In conclusion, the supplement of fucoidan could improve the fecal microbiota composition and repair the intestinal barrier function. The study suggested the use of fucoidan as an intestinal flora modulator for potential prevention of breast cancer.
- 1 July 2016
- Published by Elsevier in Virus Research
- Vol. 220, 52-56
Glypican-4 gene polymorphism (rs1048369) and susceptibility to Epstein-Barr virus-associated and -negative gastric carcinoma
- 1 July 2016
- Published by Elsevier in Virus Research
- Vol. 220, 52-56
Glypican-4 gene polymorphism (rs1048369) and susceptibility to Epstein-Barr virus-associated and -negative gastric carcinoma